The study found that prophylactic locoregional surgery (LRS) for asymptomatic patients with small intestinal neuroendocrine tumors (SI-NETs) provided no survival advantage compared with delayed LRS.
A new study found that prophylactic surgery for asymptomatic patients with small intestinal neuroendocrine tumors (SI-NETs) provided no survival advantage.
“SI-NETs have an indolent clinical course, and are often diagnosed at a late stage,” wrote the authors. “Sixty percent of patients with SI-NETs present with distant metastases, most commonly in the liver; thus a high proportion of patients are diagnosed with stage IV tumors.”
For SI-NETS patients without local tumor-related symptoms, prophylactic locoregional surgery (LRS) has been encouraged in order to prevent future intestinal obstruction, ischemia, perforation, or bleeding. However, there is a lack of data comparing benefit of prophylactic upfront LRS compared to delayed LRS.
The study, published in JAMA Oncology, analyzed the outcome of LRS in asymptomatic patients with stage IV SI-NETs compared with delayed LRS as needed. Authors collected data from 363 patients documented in the SI-NET prospective database of Uppsala University Hospital in Sweden. Patients must have had a histopathologically confirmed diagnosis of SI-NET, radiologically confirmed distant metastases, and no abdominal symptoms to be included.
Patients were split up between those who were selected for and underwent prophylactic up-front surgery within 6 months of diagnosis combined with oncologic treatment (LRS group), and those who underwent no surgery or delayed surgery as needed combined with oncologic treatment (delayed LRS group).
Of the 363 patients, 161 were in the LRS group, and 202 were in the delayed LRS group. Patients in the unmatched delayed LRS group were older and had a more advanced disease. Eighty-nine of those patients underwent delayed LRS, and 113 never underwent LRS.
A 1:1 nearest-neighbor propensity score match with a caliper width of 0.1 was implemented between the LRS and delayed LRS groups using the variables such as age, sex, calendar year at baseline, carcinoid symptoms, and the Charlson comorbidity index, a predictive factor for survival, ranging from zero to 31 points.
The results of the propensity score matching identified 2 isonumerical groups with similar baseline variables and propensity score distributions. The LRS and delayed LRS groups were comparable in median overall survival (OS) and cancer-specific survival. There was no difference in 30-day mortality or postoperative mortality rates. There was also no difference in median length of hospital stay (LOS), or LOS due to local tumor-related symptoms. Patients in the LRS group underwent more re-operative procedures.
Overall, there was no survival benefit found for patients with initial prophylactic LRS compared with delayed LRS.
While there is value in the use of LRS for patients with SI-NETs when radical resection is feasible or when symptomatic disease is present, results of this study challenge the appropriateness of the use in patients with distant metastases in the absence of local tumor-related symptoms.
“In the era of personalized treatment, maximalist surgery should be reconsidered and replaced by a comprehensive multidisciplinary approach for the optimal treatment of patients with SI-NETs,” concluded the authors.
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities
April 22nd 2025Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Rare Autoimmune Disorder Linked With Increased Risk of Certain Skin Cancers
April 21st 2025The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was particularly heightened among patients with severe mucous membrane pemphigoid.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More